OxSonics raises £9.4m in series B equity financing

9th January 2017

OxSonics, an Oxford University spinout established in 2013 to develop ultrasound therapeutics, has secured £9.4m in series B equity financing, bringing its total external fundraising to £14.2m.

The company is planning to use the investment to fund development of SonoTran, its drug delivery platform for the enhanced delivering of oncology agents to solid tumours. New and existing investors backed the round, including: Longwall Venture Partners, Oxford Technology Innovation EIS Fund, the University of Oxford, Winton Ventures, Perivoli Innovations as well as individual private investors.

For more information and the full release, please visit the OxSonics website.

Press release sign up

Ready to get in touch?

Contact Us
© Oxford University Innovation